Profit

BSE Code: | NSE Code: | ISIN: | Sector:

NSE
394.00
Change Change %
-13.50 -3.31%

Updated:21 Sep, 2018, 15:59 PM IST

BSE
395.00
Change Change %
-12.25 -3.01%

Updated:21 Sep, 2018, 16:01 PM IST

Research Report Detail

Brokerage
Analyst
Report Date Call Price@Call Target Price
Stop Loss
Current Status Time Horizon
Nomura
N/A
08-06-2017 Hold 530.60 474.00
N/A
Target Hit Long (1Y)
08-06-2018

Nomura maintains neutral on Cadila Healthcare

Cadila received approval for gLialda (Mesalamine Tabs XR) on 7 June 2017. We note that Cadila is the first company to secure approval for an oral mesalamine product in the US.We did not expect Cadila healthcare to get approval for gLialda, given the stringent bioequivalence and dissolution study guidelines issued by the USFDA.

Top